With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

The company, a spinoff from German group Eckert & Ziegler, achieved a market capitalization of 126.5 million euros ($139.7 million) at its listing price of 5.10 euros. However, shares fell below that ...

Prime Medicine, Inc. has recently entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMS) to develop and commercialize multiple prime edited ex vivo ...

You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Now that nearly all online stock brokers have eliminated deposit requirements ... One of the drugs Royalty Pharma owns a ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...

Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb ...